U.S. Genome Editing Market Size, Share & Growth Report, 2033
The U.S. genome editing market size was estimated at USD 3.55 billion in 2023 and is projected to hit around USD 16.49 billion by 2033, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.
The U.S. genome editing market is characterized by a dynamic landscape driven by rapid advancements in biotechnology and genetic engineering. Genome editing technologies, notably CRISPR-Cas9, have revolutionized the field by offering precise and efficient tools for modifying genetic material. This market encompasses a wide range of applications across various sectors, including healthcare, agriculture, and biotechnology research. In healthcare, genome editing holds immense promise for developing novel therapies for genetic disorders, cancer, and infectious diseases. In agriculture, genome editing is being utilized to enhance crop yields, improve resistance to pests and diseases, and develop sustainable farming practices. Additionally, the U.S. genome editing market is supported by robust investments in research and development, favorable regulatory frameworks, and a strong ecosystem of biotechnology companies, academic institutions, and research organizations. As a result, the U.S. genome editing market is poised for continued growth, driven by ongoing technological innovations and increasing demand for precision genetic engineering solutions.
| Report Attribute | Details |
| Market Size in 2024 | USD 4.14 Billion |
| Market Size by 2033 | USD 16.49 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 16.6% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, delivery method, mode, application, end-use |
| Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis S.A.; GenScript; AstraZeneca; Integrated DNA Technologies, Inc.; Egenesis Inc.; New England Biolabs; OriGene Technologies, Inc.; Lonza; Thermo Fisher Scientific, Inc. |
The growth in the genome editing market is driven by rising demand for synthetic genes, the application of CRISPR technology, and government funding. The expansion is further fueled by the production of genetically modified crops, genomics projects, and advancements in research and development. Innovative gene editing methods have advanced gene therapy and molecular biology significantly. The availability of user-friendly gene therapy systems and the potential for rapid genome-wide analyses also contribute to the market growth.
The U.S. accounted for over 43.9% of the global genome editing market in 2023. The advent of innovative technologies enabling easy editing of genomic DNA has unlocked a transformative period in therapeutic development. Genome editing technology has the potential to take precision medicine to the next level. Anticipated regulatory approvals for research and clinical trials involving gene editing therapies will likely boost their acceptance soon. Successful outcomes in preclinical and phase I clinical trials are projected to impact product introductions and stimulate market growth with promising opportunities.
In recent years, the market has expanded primarily due to the rising demand for synthetic genes and the increased use of CRISPR genome editing technology in various biotech sectors. The growth is expected to be propelled by increased government funding, a surge in the production of genetically modified crops, and a rise in genomics projects. CRISPR-based diagnostic tools, instrumental in COVID-19 diagnostics, also drive this growth. For example, the VaNGuard (Variant Nucleotide Guard) diagnostic test, developed by academics from Nanyang Technological University in March 2021, can identify mutated SARS-CoV-2 strains, thereby enhancing the use of CRISPR genome editing technology in the diagnostics sector.
Furthermore, ongoing advancements in gene-editing technologies significantly contribute to the market’s profitability. For instance, scientists at Harvard’s Wyss Institute for Biologically Inspired Engineering developed a new gene-editing tool called Retron Library Recombineering (RLR) in April 2021. This tool enables the execution of millions of genetic experiments simultaneously, thereby enhancing editing rates. The market expansion is driven by supportive government policies concerning synthetic biology, a growing demand for engineered genes and cells, and increased government and major corporations investments.
Developing and applying novel gene-editing techniques have marked significant progress in gene therapy and molecular biology, further propelling the market’s growth. In addition, the market growth during the projected period is fueled by the availability of easy-to-use gene therapy systems, progress in genome engineering, and the ability of gene therapy to expedite comprehensive analyses of gene function across the genome. Although gene editing technologies are confined to the basic research area in drug development, they hold great potential for detecting and validating new therapeutic targets. It also plays a great role in understanding a drug’s mechanism of action by providing a broader picture of genes involved in regulating various cell biological processes.
Biotechnology and pharmaceutical companies dominated the market and accounted for the largest revenue share of 50.25% in 2023 due to the increasing number of research activities aimed at developing new therapies. Furthermore, collaborations between pharmaceutical companies and emerging firms to innovate new technologies are prevalent. The surge in research and development efforts for new treatments is a key driver of revenue growth. In addition, the market is expected to grow due to strategic developments by major companies. For instance, in January 2022, CRISPR Therapeutics AG and Capsida Biotherapeutics Inc. entered a strategic agreement to develop innovative gene therapies using CRISPR/Cas9 technology to treat various diseases. Per the agreement, Capsida will provide its adeno-associated virus (AAV) delivery technology, while CRISPR Therapeutics will lend its genome editing expertise
Academic and research institutions are expected to grow at the fastest CAGR of 18.9% during the forecast period due to the growing adoption of technology in universities. Numerous organizations are creating educational materials for high school and college students to facilitate their understanding of gene editing processes. For instance, in January 2022, the ChristianaCare Gene Editing Institute visited high schools and colleges with its innovative CRISP in Box Educational Toolkit. This toolkit aims to raise awareness about powerful biomedical technologies like CRISPR, which are on the verge of revolutionizing disease treatment. The current kit, which only contains safe, synthetic components, cannot be used to modify living organisms. However, it serves as an effective tool to illustrate how CRISPR works.
Ex-vivo dominated the market and accounted for the largest revenue share of 50.18% in 2023 due to its benefits, such as ease of control in DNA alteration. The growth of the ex-vivo delivery segment has been fueled by an expanding clinical trial pipeline that utilizes genome editing tools. The successful completion of the Human Genome Project (HGP) has led to the discovery of nearly 7,000 new human genetic diseases. Gene therapies based on ex vivo gene editing, like CAR-T, have significantly impacted. However, most patients with genetic diseases need in vivo treatments. These treatments require clinically precise editing tools and safe, targeted delivery systems that can be scaled up to serve the entire patient population. This need is a contributing factor to the growth of these segments.
In-vivo segment is expected to grow at the fastest CAGR of 19.4% during the forecast period. The in-vivo method, which involves gene editing within the body, can treat many diseases as some cells cannot be removed and restored. In-vivo gene editing allows delivery of the nucleases by viral vector, nonviral vector, or direct delivery of nucleases protein. For instance, systemic therapy targets liver tissues to treat hemophilia, while local injections target specific tissues like muscle, brain, or eye. Many cells cannot survive outside the body or be effectively returned post-treatment, so most diseases require in-vivo genome editing.
CRISPR/Cas9 dominated the market and held the largest revenue share of 41.9% in 2023 and is expected to grow at the fastest CAGR during the forecast period. This technique, which can precisely split DNA strands and introduce new genetic data, is invaluable in gene therapy, drug development, and scientific research. CRISPR/Cas9 is favored for genome editing due to its simplicity, high efficiency, and accuracy, making it versatile for various applications. Its clinical applications have gained widespread acceptance, as demonstrated by the increasing number of ongoing clinical trials that employ gene-editing techniques to treat a broad spectrum of diseases, including AIDS, cancer, and genetic disorders. Beyond human health, this technology is also seeing growing adoption in fields like agriculture and animal breeding.
TALENs held the second-largest market share during the base year. The DNA-binding protein of TALEN technology can be engineered to identify specific DNA sequences, enabling accurate gene modification. This technique has many applications, including gene therapy, agricultural enhancement, and disease modeling. The shortcomings of CRISPR technology have led to an increase in the use of the TALEN method in certain challenging genomic regions to edit. A study released in January 2021 found TALEN to be a more appropriate tool for compact DNA studies. These types of studies are expected to drive the use of the TALEN method in research environments in the future.
Contract dominated the market with the largest revenue share of 65.15% in 2023 and is expected to grow at the fastest CAGR during the forecast period. This is due to the extensive outsourcing in the gene editing field, which offers lower costs and more operational flexibility than in-house development. The segment’s growth is expected to continue, driven by the expanding capabilities of major players in this area. For example, in December 2022, a Contract Research Organization (CRO) called Crown Bioscience, Inc. partnered with ERS Genomics Limited to access ERS’s CRISPR/Cas9 patent portfolio, enhancing its position in the gene editing market. Such initiatives will likely increase outsourcing opportunities in the genome editing sector, positively impacting market growth.
In-house is projected to experience significant growth in the upcoming years, owing to the benefits of in-house operations. These benefits include control over supply channels, improved abilities to troubleshoot processes, and the potential for scaling up in-house activities in the future, which could be advantageous in the long term. Consequently, companies like Precision BioSciences maintain their cGMP-compliant manufacturing facilities that generate genome-edited products, such as allogeneic CAR T cell therapies. These elements are expected to contribute to the segment’s revenue growth during the forecast period.
Genetic engineering dominated the market and held the highest revenue share of 68.14% in 2023 and is expected to grow at the fastest CAGR during the forecast period. This is attributed to the fast-paced advancements in gene and stem cell therapy. CRISPR gene editing’s application in human induced pluripotent stem cells (hiPSCs) has significant implications for treating various diseases. Cell line engineering, a technique that alters cell genetics to modify or create organism traits, is widely used in biotechnology, gene therapy, and drug development research. It holds the potential to revolutionize medicine. The cell line engineering market is poised for rapid expansion due to technological progress and increasing demand for customized medical treatments.
Clinical application is expected to grow at the second fastest rate of CAGR 12.8% during the forecast period. The efficiency of CHO cell lines, often used in large-molecule medicine production, is being enhanced by CRISPR technology. This has propelled the biopharmaceutical industry forward, boosting the genome editing market. Genome editing technologies and genetic engineering hold substantial growth potential in medical areas such as diagnostics and drug development. For example, the effectiveness and safety of UCART123 are being evaluated in a clinical trial funded by Cellectis S.A. for patients with relapsed/refractory acute myeloid leukemia using TALEN gene-editing technology. The application of genome editing in drug discovery and development is expected to significantly increase due to the growing demand for innovative, powerful treatments for various diseases. Genome editing can create new medicines that target genes or gene pathways, potentially leading to more efficient and specialized disease treatments.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Genome Editing market.
By Technology
By Delivery Method
By Mode
By Application
By End-use
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers